A comparison of national vaccination policies to prevent serogroup B meningococcal disease.

ABSTRACT:

Objectives

To understand the global landscape of prevention and control efforts targeting serogroup B meningococcal (MenB) disease and to identify the key challenges and gaps yet to be addressed.

Methods

We conducted a comprehensive review of policies and practices for the use of protein-based MenB vaccines (Bexsero® [GlaxoSmithKline] and Trumenba® [Pfizer]) in all countries (n = 58) where either or both vaccine is authorized for use. We searched the literature (PubMed) and websites of health ministries and other relevant agencies to identify policy documents and plans and collect information about implementation timelines, target groups, vaccines being used, recommended schedules, and coverage data. Experts in the field were contacted for additional details andclarification

SUBMITTER: Sulis G 

PROVIDER: S-EPMC9575558 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature